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1. Introduction
Platelet counts in blood are controlled by the rates of their production by megakaryocytes and
the kinetics of their removal. Alterations in either process can lead to thrombocytopenia (TCP)
or thrombocytosis. Under conditions of TCP, the spleen and liver are the sites for accelerated
platelet destruction, and in thrombocytosis, the spleen can become a supplemental breeding
ground for megakaryocytes, in addition to the bone marrow space. Humans produce and
remove 1011 platelets per day. Senile or damaged platelets are detected as such and are removed
from blood. Platelets must also be removed locally at diverse sites where they have discovered
vascular damage, attached and become activated to prevent blood leakage. The mechanism of
this local removal in the blood vascular system is not well described or understood. The
removal of platelets from flowing blood mandates a system that detects changes that accu‐
mulate in the platelet surface with age and that responds by binding and removing the platelets
when changes reach a critical level. Surface changes must either increase the availability of
clearance ligands or remove anti-clearance signals such as CD47 [1]. Changes in the platelet
surface that signal for removal include phosphatidylserine upregulation, deglycosylation of
membrane glycoproteins, in particular Gp1bα of the vWf receptor, and Ig binding. Diseases
that accelerate removal arbitrate their impact at the platelet surface.
This section highlights recent advancements in understanding how platelet lifetimes in blood
are regulated and the discovery of a surprising feedback pathway that links platelet removal
by hepatocytes in liver to platelet production in the bone marrow.
2. Sites and cells that remove senile platelets
Platelet senescence is driven by both an internal proteolytic clock and through external changes
that occur on the cell surface as they circulate in blood. Internally, platelets have an apoptotic
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mechanism that sets limits on the overall platelet lifetime at ~10 days [2]. At the time of birth,
each mature platelet has a defined quota of the pro-survival protein Bcl-x that with time
degrades, releasing its brake on the activities of Bak and Bax that subsequently induce
mitochondrial lysis, cytochrome C release, and the activation of cytoplasmic capases. Capases
disassemble the cytoskeleton and lead to the upregulation of phosphatidylserine to the platelet
surface. Cells that have phosphatidylserine on their surfaces are avidly recognized and
removed by the professional phagocytes, macrophages and immature dendritic cells. Multiple
receptors have been identified for phosphatidylserine on phagocytes including CLM-1 or
CD300f [3], Tim-4 [4], BaI1 [5], or Stabilin-1 receptor [6].
Platelets express CD47 on their surface. CD47, also called integrin associated protein [7], is a
member of the immunoglobulin superfamily that associates with the integrins, αIIbβ3 and
αvβ3, on platelets. A role for CD47 in maintaining platelets in circulation was first recognized
in knockout mice, which have platelets counts reduced by ~20% compared to normal. This
highly glycosylated surface protein is recognized by the SIRPα transmembrane protein on
phagocytes that contains two immunoreceptor tyrosine-based inhibitory domains in its
cytoplasmic domain. Hence, ligation by CD47 transmits anti-phagocytic signals to macro‐
phages, independent of the phagocytic receptor engaged, helping to prevent macrophages for
engaging phagocytic pathways involving Fc receptors.
One example where phosphatidylserine exposure can induce macrophages to remove platelets
occurs with FlnA null platelets. Mice having megakaryocytes and platelets that lack FlnA are
macrothrombocytopenic, with platelet counts reduced by 80-90%, compared to WT mice. FlnA
null platelets are unstable because they lack FlnA’s actin filament crosslinking activity and its
membrane glycoprotein attachment sites, which link the actin cytoskeleton to the plasma
membrane. FlnA constitutively binds to the GP1bα chains of the vWF complex, as well as
certain β-integrin chains. The high density of the vWfR-FlnA interaction, ~12,000 per platelet,
stabilizes the membrane by attaching it to the underlying actin cytoskeleton. Because the vWfR
is linked to the sides of actin filaments it also regulates the topology of the vWf receptor,
aligning the receptor in linear arrays on the platelet surface. When studied in vitro, FlnA null
platelets spontaneously fragment into microparticles that are 100% positive for annexin V
binding, which reports flipping of phosphatidylserine to the cell surface. Microparticles from
the FlnA null platelets are, however, rarely found in freshly isolated blood, unless macro‐
phages are first ablated in the mice using phagocytic liposomes filled with clodronate, a potent
toxin when ingested. This finding demonstrates that macrophages normally clear both FlnA
null platelets and microparticles derived from them in situ, most likely using phosphatidyl‐
serine recognizing receptors [8].
3. Sialic acid and platelet circulatory lifetime
Sialic acid terminates the N- and O-linked glycans of all cell surface glycoproteins. Desialyla‐
tion of platelet glycans was the first recognized mechanism that can target platelets for
clearance. In 1975, Greenberg and colleagues [9] showed that desialylation of platelets (and
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erythrocytes) in vitro using neuraminidase resulted in rapid removal upon retransfusion.
Subsequently, it was found that sialic acid is lost during platelet storage in vitro [10] and as
platelets age in vivo [11]. Recently, the mechanism that removes sialic acid-depleted platelets
has been identified. Studies from 2 independent labs have found that liver hepatocytes, using
their asialoglycoprotein receptor (Asgr), remove desialylated platelets as well as certain
desialylated plasma proteins.
The Asgr was one of the first receptors to be identified and characterized [12] over 40 years
ago. Each surface Asgr is a heterotrimer composed of 2 HL-1 chains and 1 HL-2 chain. Knock
out animals lacking in the expression of either chain, therefore, do not have functional Asgr
receptors on their hepatocytes. The Asgr is a C-type lectin that recognizes exposed β-galactose,
the underlying moiety to which sialic acid is linked in carbohydrate chains. Most glycoproteins
have their glycans capped by α2,3-linked sialic acid. Galactose exposure is mediated by
sialidases present in blood or released into blood by infectious bacteria. Interestingly and of
high clinical impact, the Asgr can also bind to α2,6 linked sialic acid residues on glycoproteins.
Desialylated platelets are recognized and removed by the liver Asgr [13-15]. The specific
function of the Asgr in platelet removal has been demonstrated by the following evidences:
(1) HepG2 cells bind and ingest desialylated platelets in vitro; (2) Mice lacking functional Asgrs
(HL2-/-) have high platelet counts (increased by 50% over HL2+/+) because their platelets
circulate for longer lifespans. Platelet circulatory lifetime is lengthened by 35% in the HL-2-/-
animals. Lectin profiling of platelets derived from the HL2-/- mice shows they have higher
amounts of exposed β-galactose as expected. Hence, the lengthening of platelet lifetimes in
these animals is caused by the loss of the removal system, not because the platelet surface
escapes desialylation in the circulation. This finding is expected if the Asgr routinely removes
desialylated platelets since the amount of desialylation will increase as the senile platelets
continue to circulate; (3) Conversely, St3gal4-/- mice that lack the main sialyltransferase enzyme
responsible for the linkage of sialic acid to galactose, have low platelet counts and short platelet
circulation lifetimes. Once again, platelets harvested from these null mice have high levels of
exposed galactose that bind the RCA I lectin avidly. Circulation times for these platelets can
be extended to near normal by transfusion of them into HL2-/- mice. This again demonstrates
the central role of the Asgr in recognizing and removing desialylated platelets. (4) Last, platelet
desialylation in vitro using sialidases or in situ following injection of sialidase causes a rapid
clearance of platelets from blood in WT mice, but not HL2-/-mice, in a process that is not altered
by macrophage ablation.
4. Feedback between liver and bone marrow
The importance of hepatocyte-platelet interaction extends beyond simple removal, as the
recognition and ingestion of platelets by the Asgr generates cytoplasmic signals in hepatocytes
that induce the formation and secretion of cytokines to promote marrow and megakaryocyte
growth and maturation. In this case, the key cytokine produced in response to platelet
ingestion is thrombopoietin [16]. Thus, the hepatocyte-platelet interaction directly feeds back
to megakaryocytes in marrow, helping to stimulate platelet production.
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5. Platelet reactive receptors on macrophages
In addition to its receptors that recognize phosphatidylserine, macrophage surfaces are
festooned with receptors that can ingest damaged and/or diseased platelets. One group
includes the lectin receptors that recognize carbohydrate alterations in platelet glycoproteins.
The phagocytic integrin, αMβ2, recognizes and removes chilled and rewarmed platelets that
release glycosylases causing β-GlcNAc moieties to expose on N-linked GP1bα glycans. In
addition, a second domain on αMβ2 recognizes a different portion of GP1bα [17]. Mannose
receptors are a second example of a receptor that detects glycan alterations, recognizing
underlying mannose moieties exposed by glycosylases [18]. Fcγ receptors remove Ig-coated
platelets from blood and when anti-platelet Igs are present their effectiveness leads to throm‐
bocytopenia.
6. Diseases causing accelerated platelet clearance by macrophages
Accelerated clearance requires either the accumulation of opsonins on the platelet surface such
as Igs and complement or the presence of agents in blood that remove protective molecules.
Both types of mechanisms occur.
There are many examples of acquired or induced immune thrombocytopenia that cause
platelet removal when anti-platelet Igs are generated, deposited on platelets, and are detected
by Fcγ receptors on macrophages. These include congenital and drug or pathogen induced
thrombocytopenia. In general, platelet clearance is primarily driven by splenic macrophages,
a process that can result in splenomegaly. In many cases, patients having ITP, respond well to
anti-Fc antibody treatment.
7. Platelet clearance mediated by hepatocytes
Bacterial-derived sialidases, released into blood during sepsis, cause platelet counts to drop
precipitously. The target of the blood born bacterial sialidases is sialic acid that caps N-linked
glycans on GP1bα, as demonstrated using mice lacking GP1bα [19], which are resistant to
clearance induced by pneumococcal sepsis in WT mice. Cleavage of sialic acid on GP1bα
exposes underlying galactose moieties that are recognized by the Asgr [13]. Animals lacking
a functional Asgr do not accelerate their platelet clearance in response to sepsis.
A related process accounts for the circulation failure of platelets transfused after rewarming
from refrigerated storage. Resting platelets contain sialidases that are stored in an internal
compartment that can be released by activation [15, 20]. Rewarming from the cold releases a
portion of the sialidase activity to the platelet surface and into the storage media, a process
that mediates desialylation of the platelet surface glycoproteins. Since the accelerated clearance
of chilled and rewarmed platelets is to a large extend ablated in mice lacking the Asgr
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(HL-2-/- mice), it is the main receptor that recognizes and removes cold damaged platelets.
Ablation of macrophage function in HL-2-/- mice further restores platelet circulation by 15-20%.
Hence, macrophages also participate in clearance.
8. Accelerated platelet clearance in Wiskott-Aldrich syndrome
Mutation, truncation and/or deletion of WASp, a protein encoded on the X-chromosome and
expressed by blood cells, results in a profound lymphocyte dysfunction that severely com‐
promises the immune system. Severe thrombocytopenia (TCP) is also a signature component
of the Wiskott-Aldrich syndrome; WAS platelets are small and have shortened circulatory
lifetimes. WAS patients produce diverse autoantibodies and WAS platelets collect higher
amounts of surface-associated immunoglobulins (Igs) than do normal platelets [21]. Many
human WAS patients respond to splenectomy with increased platelet counts, despite the
finding that all patients have been found to be refractory to anti-Fcγ antibodies. Unlike ITP,
homologous platelets circulate normally in WAS patients strongly suggesting a more complex
mechanism for removal that involves receptors other than Fc.
WASp KO mice have been shown to retain the key features of WAS disease, having T and B
lymphocyte dysfunction, enlarged spleens, low platelet counts (70% of normal) and shortened
platelet survival times in blood. It has been widely believed that platelet clearance is acceler‐
ated in these animals because the autoimmune aspect of the disease results in increased Igs
bound to the platelets surface that led to recognition by splenic macrophages. However, as in
the human conditions, normal platelets, when transfused into WASp KO mice, circulate
normally indicating that a simple anti-platelet antibody mediated clearance is not the mecha‐
nism. In mice, splenectomy has been shown to be without effect on the clearance rate.
In efforts to identify the mechanism of removal, WASp Null platelets were transfused into
mice lacking specific phagocytic receptors. A survey on macrophage receptors failed to reveal
any in which the WASp null platelets had enhanced circulatory lifetimes. However, WASp
KO platelets were found to circulate normally in Asgr null mice, a finding once again posits
the Asgr as a central molecule involved in the recognition and removal of damaged platelets.
The surface of WASp KO platelets is, however, not desialylated and lectin binding studies have
instead revealed hypersialylation. This sialylation occurs specifically in the 2,6 linkage, not the
normal 2,3 linkage. Critically, the Asgr also receptor recognizes this unique sialic linkage,
leading to binding and platelet removal. The carrier of this sialic acid turns out to be surface
bound Ig and sialylation of its Fc N-linked glycan shifts recognition of the Fc domain from
macrophages to the hepatocytes.
Interestingly, the source of the 2,6 sialyltranferase (ST6Gal1) is liver hepatocytes, which make
and secrete this enzyme into blood. This blood enzyme is an acute phase reactant protein,
upregulated in liver in response to bacterial sepsis, cancer, or inflammation. In this case,
platelet ingestion itself, feedbacks to upregulate ST6Gal1 mRNA transcription and translation
and this increases by 3-4 fold the blood levels of this enzyme.
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9. Cause of surface alterations that lead to the deposition of Igs on the
WASp KO platelet
The modification(s) in WASp KO platelet surface that leads to Ig production by WASp KO B-
lymphocytes and Ig-binding are not known. Since WT platelets do not collect Igs in WASp KO
plasma or have accelerated clearance in WASp KO animals, surface alterations are specific for
the WASp KO platelets. Because WASp is a protein that interacts with the actin cytoskeleton,
it is likely that internal cytoskeletal changes in its absence result in an altered topology of
platelet receptors or the expression of the neo-epitope. In general, platelet function in the
absence of WASp is near normal although as the precision of assays increase, some differences
have now been recognized. Active platelets lack small focal actin assembly sites in the absence
of WASp, although spreading and filopodial formation are normal. In resting platelets, failure
to express WASp alters the stability of microtubules, increasing their acetylation and slowing
their turnover. How these internal changes alter the surface remains for future studies.
10. Platelet production
The basic processes involved in megakaryocyte commitment, maturation and platelet forma‐
tion are well described although many precise details remain to be clarified. Megakaryocytes
derive from a renewable population of hematopoietic stem cells that continuously enter the
MK/platelet lineage and once committed to produce platelets, live for only a few more weeks
before they are converted into hundreds of platelets. Proplatelet and platelet production
requires a massive enlargement in MK size that is driven by high levels of mRNA transcription
from their amplified polyploid nuclei followed by mRNA translation into platelet essential
components. This includes the production of an abundant internal network of membranes
called the demarcation membrane system (DMS) that dramatically increases the apparent
membrane to surface ratio during proplatelet formation, platelet specific granules, and the
synthesis of large amounts of the cytoskeletal machinery that is used to form and fill assem‐
bling platelets.
As MKs mature, they develop an extensive network of internal membranes called the DMS
that are enriched phosphatidylinositol 4,5 bisphosphate and the vWf receptor [22] and are used
as the primary membrane source for proplatelet elongation. Recent studies by Eckly et al [23]
have begun to shed some light on DMS formation, describing how the DMS forms and matures.
To form the DMS, the plasma membrane of megakaryocytes enfolds at specific sites and a
perinuclear pre-DMS is generated. Next, the pre-DMS is expanded into its mature form by
material added from golgi-derived vesicles and endoplasmic reticulum-mediated lipid
transfer. This structural description is in accordance with the studies on platelet glycosyl‐
transferases, which arrive early in the forming DMS and eventually make their way to the
megakaryocyte and platelet surfaces [24]. Only a small number of proteins have been identified
thus far to participate in the DMS formation process based on alterations in its structure in
certain knockout animals. Gross disruptions of this network are found in megakaryocytes
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isolated from either filamin A knockout or pacsin2 knockout mice, the latter of which connects
GP1bα to the actin cytoskeleton and binds pacsin2, a molecule that deforms membrane. The
relationship between the DMS and the platelet open canalicular system (OCS) is not clear. The
OCS, like the DMS, is a unique anastomosing network of internal membrane tubes that is
connected to the plasma membrane at multiple points. The internal canals of the OCS can be
identified because they contain vWfR, and hence can be labeled with anti-GP1bα antibodies
(Kahr et al).
To release platelets, megakaryocytes in the marrow space move to and nestle the marrow
sinusoids where they project their proplatelet protrusions into the blood flow [25, 26]. Whether
all proplatelets are directed to grow specifically into the sinusoids or if only some of the
proplatelets elaborated by a MK find their way into the sinusoids is unknown, although living
MKs in marrow have been observed to have many proplatelet projections, some of which
project into the marrow space while others project into the sinusoids [27]. Studies have
demonstrated that proplatelet fragments considerably larger than platelets are released by
MKs into blood [26, 27] and that proplatelets can be both found, and can mature into platelets,
in blood [28].
The state of our current knowledge of the mechanics of proplatelet production has come
primarily from studies on MKs in culture. This work has clarified the essential role of micro‐
tubules, which were recognized early as the most prominent structure found within the MK
projections [29] and that proplatelet and platelet production were adversely affected by MT
poisons [30]. Subsequent gene expression studies established the importance of β1-tubulin, a
tubulin isoform specific for MKs, to the maturation of MKs into proplatelet producing
machines [31]. More recent studies using gene deleted MKs have begun to reveal the precise
roles of specific proteins in proplatelet and platelet production and these are highlighted
below.
Signals that initiate proplatelet formation, if present, remain undefined and it remains possible
that the program to make platelets starts when the synthesis of cytoskeletal proteins for this
process reaches a critical mass. From a mechanical view, centrosome dissolution precedes
proplatelet extension, and the release of MTs from these multiple nucleating sites correlates
best with the start of proplatelet elaboration. Released MTs first collect as bundles in the MK
cortex where they are driven apart by their associated motor protein, dynein. These MT-dynein
reactions deform the membrane outward and generate the structural motor of the proplatelet,
which is a MT bundle that folds over in the proplatelet tip and runs back into the shafts. Each
bundle is composed of many MTs that are continuously growing and shrinking from their
ends. Six types of behaviors characterize the elaboration of proplatelets: elongation, branching,
pausing, fusions, fragmentations, and retractions. While the average elongation rate for
proplatelets over time is ~1 µm/min, extension normally occurs in bursts and pauses. Burst
rates greatly exceed the average rates and under flow, and rates of >30 µm/min have been
observed. These rates correlate well with the sliding rates of MTs within the bundles. Pauses
in proplatelet extension are not caused by a stoppage in MT sliding, which continues at a 1-6
µm/min rate. Sliding reactions in paused proplatelets appear to build tension into the bundle
which when released leads to branching and/or fragmentation. This implies that there are
regions within the bundles where MTs are crosslinked to increase resistance or they are
Production and Destruction of Platelets
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pushing against resistive structures. Branching is a modified form of extension derived from
tension asymmetry where a portion of the MT bundle detaches from the mother bundle and
elongates rapidly forming a new tear shaped structure and proplatelet shaft. Retraction, where
the sliding could either reverse or all crosslinking derived tension releases, could serve to
subfragment the proplatelets.
In addition to playing a crucial role in proplatelet elongation, the microtubules lining the shafts
of proplatelets serve a secondary function — tracks for the transport of membrane, organelles,
and granules into proplatelets and assembling platelets at proplatelet ends [32]. Individual
organelles are sent from the cell body into the proplatelets, where they move bidirectionally
until they are captured at proplatelet ends. Immunofluorescence and electron microscopy
studies indicate that organelles are in direct contact with microtubules, and actin poisons do
not diminish organelle motion. Therefore, movement appears to involve microtubule-based
forces. Bidirectional organelle movement is conveyed in part by the bipolar organization of
microtubules within the proplatelet, as kinesin-coated beads move bidirectionally over the
microtubule arrays of permeabilized proplatelets. Of the two major microtubule motors —
kinesin and dynein — only the plus-end-directed kinesin is situated in a pattern similar to
organelles and granules, and is likely responsible for transporting these elements along
microtubules. It appears that a twofold mechanism of organelle and granule movement occurs
in platelet assembly. First, organelles and granules travel along microtubules and, second, the
microtubules themselves can slide bidirectionally in relation to other motile filaments to
indirectly move organelles along proplatelets in a “piggyback” fashion
Although microtubules and associated motor and regulatory proteins power proplatelet
motility, elimination of certain actin cytoskeletal-associated proteins have now been demon‐
strated to modulate this process. These include a number of actin-associated proteins, mem‐
brane contouring proteins, and signaling proteins.
11. Influence of actin-associated proteins on thrombopoiesis
Since proplatelets elongate, but do not branch, in the presence of the actin disrupting drug
cytochalasin B, it is surprising that the deletion of certain actin associated proteins from the
megakaryocyte lineage leads to macrothrombocytopenia. It seems likely that the removal of
actin modulating proteins, alters and/or increases filamentous actin (F-actin) and cytoskeletal
structure to have a dominant inhibitory effect proplatelet maturation and/or platelet release
from proplatelets.
12. Actin crosslinking proteins
Three proteins, filamin A (FlnA), actinin 1 (Actn1) and spectrin, that crosslink F-actin using a
related F-actin binding site, are critical components of the mature platelet cytoskeleton and
regulate proplatelet formation and motility.
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FlnA. FlnA, an elongated homodimer 160 nm in length, is an essential actin filament cross‐
linking and scaffolding protein that interacts with multiple platelet proteins including the
vWfR, β-integrins, migfilin, Syk, and filGAP, in addition to crosslinking F-actin. Each FlnA
subunit has an N-terminal actin-binding domain (ABD) that is followed by 24 Ig-like repeats,
the last of which contains the self-association site for molecules. In platelets, FlnA crosslinks
the actin filaments posited beneath the plasma membrane into a rigid network and using its 2
Gp1bα binding sites attaches actin filaments to the vWfR. Since there are 12,000 molecules of
FlnA per platelet, and 25,000 Gp1bα chains, the amount of FlnA is sufficient to link 95% of the
vWfR to actin since each FlnA binds two Gp1bα chains. Loss of this linkage, either by the failure
to express stable GP(1bαβ9)25 complexes on the platelet surface, or by the absence of cyto‐
plasmic FlnA in conditional mice whose MK/platelet lineage lacks FlnA expression, results in
a macrothrombocytopenia in which platelet counts are reduced by 80-90%. Not only does the
loss of FlnA result in large platelets, the FlnA-null platelets are extremely fragile, and sponta‐
neously subfragment within blood, resulting in short circulation lifetimes and accelerated
removal of the fragments by macrophages. The enlarged platelet phenotype of the FlnA null
platelets is very similar to that found in patients having Bernard-Soulier Syndrome, which
because they do not express stable surface vWfR, also lack the important FlnA-mediated vWfR-
cytoskeletal attachments. Human periventricular heterotopia patients with FlnA mutations
and/or truncations have also been found to bleed and have low platelet counts [33-35].
Interestingly, failure to express FlnA in MKs disorganizes the DMS system. Alterations in the
DMS in the absence of FlnA may involve its lipid-deforming partner, pacsin2 (see below).
Proplatelet elaboration is accelerated in FlnA null MKs in vitro. Hence, FlnA imposes restraints
on the timing of platelet production.
Actn1. Actinin dimers are short rods, 40 nm in length, built from an antiparallel, side-to-side
alignment of its subunits. Each subunit chain has an NT ABD followed by 4 α-helical repeats,
related in structure to those in spectrin, and last, an EF hand motif. In nonmuscle cells, binding
of the actinin isoforms that are expressed (Actn1 and Actn4) to F-actin are regulated by calcium
although the muscle isoforms have lost this sensitivity. Human patients with macrothrombo‐
cytopenia have been identified that express mutant actn1 molecules having sequence changes
within their NT actin binding site [36]. Since these actn1 mutants reduce the proplatelet
formation and cause MKs to elaborate thick proplatelets when expressed in mouse MKs, it is
believed actinin function can alter the MK to proplatelet transition. Actn1 is expressed in
platelets at levels equivalent to FlnA [37].
Spectrin. Platelets, like erythrocytes, have a planar membrane skeleton that laminates the
plasma membrane and is linked to the underlying actin cytoskeleton. This skeleton is com‐
posed of twisted and elongated spectrin tetramers that interconnect by binding to the barbed
ends of actin filaments, a interaction that is promoted by β-adducin, a molecule that binds to
both spectrin, near its ABD, and the barbed filament end of an actin filament [38]. Tetramers
are assembled from heterodimers; α,β dimers are 100 nm in length, are bipolar and side-to-
side constructs, in which the β-chain donates the actin binding domain on one end (NT of the
b-chain), with the self-association domain posited on the other end. Head-to-head binding of
dimers forms tetramers, a process that is dynamic and can be disrupted using small fragments
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of β-chain C-Terminal to compete for this binding site. When such negative dominant
fragments are expressed into MK cultures, proplatelet elaboration is blocked. Similarly, the
exposure of permeabilized proplatelets with this small C-Terminal protein construct results
in blebbing and swelling, and ultimately complete loss of cytoskeletal integrity.
Myosin 2A and Rho/ROCK.  MYH9 gene disorders (myosin 2a) cause May-Hegglin and
the related Epstein,  Fechtner,  Sebastian,  and Alport  syndromes in humans,  all  of  which
have  thrombocytopenia.  However,  the  myosin  2A  story  is  complex.  Gene  inactivation
studies in mice have shown that loss of myosin 2a protein expression in MKs accelerates
the production of large platelets, while MYH9 gene mutations in humans have dominant
negative  effects  and  reduce  platelet  production.  The  most  severe  mutations  that  effect
platelet counts,  posit within the myosin head motor domain, while mutations in the tail
domain,  allow somewhat higher,  but still  abnormal platelet  counts.  The general  consen‐
sus on these myosin-mediated defects  are  that  myosin activity  is  necessary to  constrain
proplatelet formation in MKs as they mature and that inactivation of myosin thus plays a
role in initiating proplatelet elaboration. In addition, since myosin activity is regulated by
MLC  phosphorylation,  modification  of  pathways  that  regulate  either  the  kinases  or
phosphatase activities that are directed toward myosin can lead to phenotypes similar to
those found for myosin mutant or loss of function.
Platelet specific RhoA deficiency causes macrothrombocytopenia with platelet counts reduced
by ~50% from normal. The RhoA-/- platelets have many functional defects that cause animals
to readily bleed, but they have normal lifetimes in blood [39]. One pathway by which RhoA
deficiency may affect MK maturation and platelet formation is through ROCK modulation of
myosin 2a activity in MKs. RhoA activates ROCK, inhibiting myosin LC phosphatase and
hence leading to increased myosin LC phosphorylation. This activity is thought to restrain
proplatelet elaboration and thus RhoA deficiency to release this brake, causing premature
proplatelet formation and leading to enlarged and dysfunctional platelets.
Protein Megakaryocyte
phenotype
Proplatelet
phenotype
Platelet phenotype Clearance
Phenotype
References
GP1ba KO Large, fragile [19]
Filamin A KO Accelerated
proplatelet
elaboration, altered
DMS
Accelerated 10-20% of normal:
Large, fragile
[8]
Actinin 1 ABD
mutants
Decreased
proplatelet
number, increased
proplatelet
thickness
Reduced, thickened Large [36]
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Protein Megakaryocyte
phenotype
Proplatelet
phenotype
Platelet phenotype Clearance
Phenotype
References
Nonmuscle
myosin
HC IIA KO
Increased,
formation
accelerated
Heterogenous,
Reduced by 70%
Normal [41]
Dynamin 2 KO Reduced, thickened 20% of normal, size
highly variable
CIP4 KO Reduced [42]
Pacsin 2 KO Normal
WASp or
WIP KO
Accelerated Slightly small Accelerated [43]
β1-tubulin Compensate by
upregulating β2
and β5-tubulin
Proplatelet
formation blocked
Amorphic, reduced
by 70-75%
[44]
Rab27b [45]
Cofilin-1 Large [46]
ADF normal 90% of normal,
size normal
[46]
ADF/Cofilin1 Numbers increased
3X; DMS and
cytoplasmic
structure altered
decreased 5% of normal
count; sizes
variable, amorphic
[46]
Actin interacting
protein
(Aip1/Wdr1)
Defective
megakaryo-
poiesis: small,
DMS abnormalities
20% of normal:
large
Normal [40]
Profilin 1 Large, size variable [47]
RhoA 50% of normal,
large -125%
Slight increase in
turnover rate
[39]
Spectrin Proplatelets
disrupted by dimer-
dimer self-
association inhibitor
[48]
Tmod3 Altered DMS Enlarged tips Large, decreased
count
[49]
Table 1. Effect of Mouse KOs on Platelet Production and/or Platelet Clearance.
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Cofilin-1/ADF and Aip1 (Wdr1]. Cofilin-1 and ADF are highly homologous protein isoforms
in the ADF/cofilin family that accelerate actin turnover in cells. The third member of this family,
m-cofilin or cofilin-2, is expressed only in muscle tissue. Cofilin/ADF bind along the sides of
actin filaments, preferentially targeting ADP-subunits, and thereby, recognize the old portions
of filaments. Binding induces a twist in the filament, causing its severing. Exposure of low
affinity filament ends following the severing event, promotes dissociation from these ends,
and this stimulates actin filament turnover in cells. Conditional mice lacking cofilin-1 have
been produced. When cofilin-1 is specifically deleted form the MK/platelet lineage, large
platelets result and platelet counts are mildly reduced (60-80% of normal). ADF-/- mice, on the
other hand, have near normal platelet counts and normal platelet function. However, when
ADF-/- mice are crossed with the mice carrying the floxed cofilin-1 allele, platelet production
in the DKO offspring is severely diminished. The morphologies of the released platelets are
highly variable, as the normal discoid space is distorted by their dense fillings of actin
filaments. In agreement with these mouse studies, proplatelets are sparse on the double
knockout MKs in vitro.
Cofilin is regulated by Aip1, a protein that binds and enhances filament severing /actin
depolymerization activity. The importance of this protein to platelet production has been
demonstrated [40]. N-ethyl-N-nitrosourea mutagenesis generated mice with profound
thrombocytopenia, bleeding, and enlarged, amorphic platelets contain a gene mutation that
was mapped to Wdr1 gene. The high degree of similarity to the phenotype of in the ADF/cofilin
double knockout, strongly suggests both proteins are in the same thrombogenesis effector
pathway.
Profilin1A and Wasp/Wip. Profilin is a small protein that promotes filament assembly. It binds
ADP-monomers, converting them to ATP-monomers, which are permitted to only interact
with the high affinity end of actin filaments (barbed end with respect to myosin S1 binding).
Mice whose MKs/platelets specifically lack profilin 1 have macrothrombocytopenia with
counts reduced by 40-50%. Platelet turnover is accelerated and the mature platelets have only
a sparse internal actin cytoskeleton. Surprisingly, although their actin cytoskeleton is disrupt‐
ed, profilin null platelets have a robust MT cytoskeleton with a thickened MT coil and more
stable hyper-acetylated microtubules.
In  certain  ways,  the  profilin  1  KO  phenotype  is  similar  to  the  behavior  of  platelets  in
Wiskott-Aldrich syndrome,  or  in  WASp or  WIP KO mice.  WASp is  a  signaling protein
promotes actin assembly system, binding to Arp2/3 when activated by binding of  GTP-
cdc42. However, the bulk of studies performed on human WAS platelets or platelets derived
from KO mice revealed normal and ever hyper-function for the WASp null platelets. Human
patients have low platelet counts that are caused by accelerated platelet clearance, a process
that lowers the platelet count in the Wasp/Wip KO mice. Recently studies have shown the
MT  ring  in  platelets  from  WAS  patients  to  be  hyper-acetylated,  like  the  profilin  1  KO
platelets. However, in the WAS syndrome, platelets in the circulation are small, not large,
as is found in the Profilin null animals.
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Figure 1. Life cycle of the platelet. Megakaryocytes in the bone marrow release proplatelets into the blood where they
mature into platelets. If damaged, platelets are detected and removed by splenic macrophages and liver Kupffer cells.
As platelets age in the circulation they become desialylated. The fate of desialylated platelets differs from that of acute‐
ly damaged platelets. Desialylated platelets are recognized and are removed from the blood in the liver sinusoids by
liver hepatocytes using their Asgr. Platelet ingestion by hepatocytes stimulates them to produce TPO and release it
into the blood.
CIP4/Pacsin2/Dynamin. Membrane deforming proteins that use F-BAR domains curve
membranes, or GTP as an energy source to bud vesicles from membranes, are necessary for
normal MK maturation and platelet release.
CIP4. CIP4 is a F-Bar containing, Cdc42 interacting and WASp binding protein. CIP4-/- mice
have a mild thrombocytopenia with a 25% decrease in platelet counts. MK numbers and ploidy
are normal in the KO mice but isolated MKs from these mice are less effective in producing
proplatelets in culture.
Pacsin 2. Pacsin 2, the only family member expressed in mouse platelets, is a FlnA partner that
has an F-BAR and SH3 domain that bindings dynamin and N-WASp. Pacsin2 plays an
important role in organizing internal membranes in platelets and megakaryocytes. In platelets,
it locates at the entrances of the OCS. In MKs it is dispersed throughout the internal anasto‐
mosing network of DMS membranes. FlnA binding is important for its functions as the
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distribution of pascin2 and the arrangement of internal membranes is grossly altered in FlnA
null MKS.
Dynamin. Dynamins are a family of three cytoplasmic mechanochemical proteins (DNM1-3)
that regulate membrane dynamics with actin during such processes as cytokinesis, budding
of transport vesicles, phagocytosis, and cell motility. Dynamin 2 and 3 are upregulated as MKs
mature and iRNA knockdown of DNM3 has been reported to interfere with maturation and
proplatelet production in vitro. Specific inactivation of the DNM2 gene in mice MKs/platelets
profoundly diminishes platelet production and function.
Figure 2. Platelet ingestion stimulates TPO signaling to the bone marrow. As platelets are detected and removed by
the Asgr, the Jak-STAT pathway is activated. This leads to TPO mRNA transcription and translation, increasing blood
TPO levels.
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Figure 3. Steps in MK maturation and proplatelet release. (1) Immature MK. Microtubules radiate outward from cen‐
trosomes and DMS has not developed. (2) Ploidy increases, the pre-DMS begins to form, the centrosomes dissolve, and
the released microtubules move out to the cell cortex and form bundles. (3) Ploidy increases to 8-16n, the DMS and
platelet specific granules are produced, the cytoplasm has become enriched in cytoskeletal proteins, and the sliding of
the MT within the bundles has begun. Sliding elongates proplatelets into the venous sinusoids and they are released
into blood. (4) Platelets mature from proplatelets and preplatelets that release into blood.
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Figure 4. Localization of microtubules within proplatelets. Immunofluorescence studies on murine megakaryocytes
grown in culture and labeled with β1-tubulin antibodies indicate that microtubules line the entire length of proplate‐
lets. The hallmark features of proplatelets, including the tip, swellings, shafts and branch points are visible.
Author details
Joseph Jr Italiano and John Hartwig*
*Address all correspondence to: hartwig@rics.bwh.harvard.edu
Hematology Division, Department of Medicine, Brigham & Women's Hospital, Harvard
Medical School, Boston, MA, USA
References
[1] M. Olsson, P. Bruhns, W. Frazier, J. Ravetch, P.-A. Olderborg, Platelet homeostasis is
regulated by platelet expression of CD47 under normal conditions and in passive im‐
mune thrombocytopenia. Blood 105, 3577 (2005).
[2] K. Mason et al., Programmed anuclear cell death delimits platelet life span. Cell 128,
1173 (2007).
The Non-Thrombotic Role of Platelets in Health and Disease18
[3] L. Tian et al., p85a recruitment by the CD300f phosphatidylserine receptor mediates
apoptotic cell clearance required for autoimmunity suppression. Nature Comm.,
(2014).
[4] M. Miyanishi et al., Identification of Tim4 as a phosphatidylserine receptor. Nature
450, 435 (2007).
[5] D. Park et al., BAI1 is an engulfment receptor for apoptotic cells upstream of the
LMO/Dock180/Rac module. Nature 450, 192 (2007).
[6] S.-Y. Park et al., Rapid cell corpse clearance by stabilin-2, a membrane phosphatidyl‐
serine receptor. Cell Death Differ. 15, 192 (2008).
[7] E. Brown, W. Frazier, Integrin-assocated protein (CD47) and its ligands. Trends Cell
Biol. 11, 130 (2001).
[8] A. Jurak Begonja, K. M. Hoffmeister, J. H. Hartwig, H. Falet, FlnA-null megakaryo‐
cytes prematurely release large and fragile platelets that circulate poorly. Blood 118,
2285 (2011).
[9] J. Greenberg, M. Packham, J. Cazenave, H. Reimers, J. Mustard, Effects on platelet
function of removal of platelet sialic acid by neuraminidase. Lab Invest. 32, 476 (1975).
[10] G. Soslau, J. Giles, The loss of sialic acid and its prevention in stored human platelets.
Thromb. Res. 26, 443 (1982).
[11] M. Steiner, S. Vancura, Asymmetirical loss of sialic acid from membrane glycopro‐
teins during platelet aging. Thromb. Res. 40, 465 (1985).
[12] G. Ashwell, A. Morell, The role of surface carbohydrates in the hepatic recognition
and transport of circulating glycoproteins. Adv. Enzymol. Relat. Areas Mol. Biol. 41, 99
(1974).
[13] P. Grewal et al., Inducing host protection in pneumococcal sepsis by preactivation of
the Ashwell-Morell receptor. Proc. Nat.. Acad. Sci, USA 110, 20218 (2013).
[14] P. Grewal et al., The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Na‐
ture Med. 14, 648 (2008).
[15] V. Rumjantseva et al., Dual roles for hepatic lectin receptors in the clearance of chilled
platelets. Nat Med 15, 1273 (Nov, 2009).
[16] R. Grozovsky, A. Begonja, J. Hartwig, H. Falet, K. Hoffmeister, The Ashwell-Morell
receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling.
Nat.Med In press, (2014).
[17] D. Simon et al., Platelet glycoprotein Ibα is a counterrecptor for the leukocyte integrin
mac-1 (CD11b/CD18). J. Exp. Med. 192, 193 (2000).
[18] R. Ezekowitz, K. Sastry, P. Bailly, A. Warner, Molecular characterization of the hu‐
man macrophage mannose receptor: demonstration of multiple carbohydrate-recog‐
Production and Destruction of Platelets
http://dx.doi.org/10.5772/60678
19
nition domains and phagocytosis of yeasts in Cos-1 cells. J. Exp. Med. 172, 1785
(1990).
[19] J. Ware, S. Russell, Z. Ruggeri, Generation and rescue of a murine model of platelet
dysfunction: the Bernard-Soulier syndrome. Proc. Natl. Acad. Sci., USA 97, 2803
(2000).
[20] A. L. Sorensen et al., Role of sialic acid for platelet life span: exposure of beta-galac‐
tose results in the rapid clearance of platelets from the circulation by asialoglycopro‐
tein receptor-expressing liver macrophages and hepatocytes. Blood 114, 1645 (Aug 20,
2009).
[21] L. Corash, B. Shafer, R. Blasese, Platelet-associated immunoglobulin, platelet size,
and the effect of splenectomy in the Wiskott-Aldrich syndrome. Blood 65, 1439 (1985).
[22] H. Schulze et al., Characterization of the megakaryocyte demarcation membrane sys‐
tem and its role in thrombopoiesis. Blood 107, 3868 (2006).
[23] F. Pertuy et al., Myosin IIA is critical for organelle distribution and F-actin organiz‐
tion in megakaryocytes and platelets. Blood 123, 1261 (2014).
[24] H. H. Wandall et al., The origin and function of platelet glycosyltransferases. Blood
120, 626 (Jul 19, 2012).
[25] J. Radley, Ultrastructural aspects of platelet production. Megakaryocyte Development
and Function, 387 (1986).
[26] O. Behnke, A. Forer, From megakaryocytes to platelets: platelet morphogenesis takes
place in the bloodstream. European J. Hematology 60, 3 (1998).
[27] T. Junt et al., Direct visualization of thrombopoiesis in the bone marrow of living
mice. Science 317, 1767 (2007).
[28] J. N. Thon et al., Cytoskeletal mechanics of proplatelet maturation and platelet re‐
lease. J Cell Biol 191, 861 (Nov 15, 2010).
[29] R. Leven, Megakaryocyte motility and platelet formation. Scanning microscopy 1, 1701
(1987).
[30] F. Tablin, M. Castro, R. Leven, Blood platelet formation in vitro. The role of the cytos‐
keleton in megakaryocyte fragmentation. J. Cell Sci. 97, 59 (1990).
[31] Y. Chang et al., Proplatelet formation is regulated by the rho/ROCK pathway. Blood
109, 4229 (2007).
[32] S. R. Patel et al., Differential roles of microtubule assembly and sliding in proplatelet
formation by megakaryocytes. Blood 106, 4076 (Dec 15, 2005).
[33] S. Feng, X. Lu, J. Reséndiz, M. Kroll, Pathological shear stress directly regulates plate‐
let aIIbb3 signaling. Am. J. Cell Physiol. 291, C1346 (2006).
The Non-Thrombotic Role of Platelets in Health and Disease20
[34] Y. Feng, C. Walsh, The many faces of filamin: a versatile molecular scaffold for cell
motility and signalling. Nature Cell Biol. 6, 1034 (2004).
[35] J. W. Fox et al., Mutations in filamin 1 prevent migration of cerebral cortical neurons
in human periventricular heterotopia. Neuron 21, 1315 (1998).
[36] S. Kunishima et al., ACTN1 mutations cause congenital macrothrombocytopenia. Am.
J. Human Gen. 92, 431 (2013).
[37] S. Rosenberg, A. Stracher, K. Burridge, Isolation and characterization of a calcium-
sensitive α-actinin-like protein from human platelet cytoskeletons. J. Biol. Chem. 256,
12986 (1981).
[38] K. Barkalow, J. Italiano Jr, Y. Matsuoka, V. Bennett, J. Hartwig, a-Adducin dissociates
from F-actin filaments and spectrin during platelet activation. J. Cell Biol. 161, 557
(2003).
[39] I. Pleines et al., Megakaryocyte-specific RhoA deficiency causes macrothrombocyto‐
penia and defective platelet activation in hemostasis and thrombosis. Blood 119, 1054
(2012).
[40] B. Kile et al., Mutations in the cofilin partner Aip1/Wdr1 cause autoinflammatory dis‐
ease and macrothrombocytopenia. Blood 110, 2371 (2007).
[41] S. Kunishima et al., Mutations in the NMMHC-A gene cause autosomal dominant
macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian
syndrome). Blood 97, 1147 (2001).
[42] Y. Chen et al., Loss of the F-BAR protein CIP4 reduces platelet production by impair‐
ing membrane-cytoskeleton remodeling. Blood 122, (2013).
[43] S. Sabri et al., Deficiency in the Wiskott-Aldrich protein induces premature proplate‐
let formation and platelet production in the bond marrow compartment. Blood 108,
134 (2006).
[44] H. Schwer et al., A lineage-restricted and divergent b tubulin isoform is essential for
the biogenesis, structure and function of mammalian blood platelets. Curr. Biol. 11,
579 (2001).
[45] S. Tiwari et al., A role for Rab27b in NF-E2-dependent pathways of platelet forma‐
tion. Blood 102, 3970 (2003).
[46] Bender M et al., ADF/n-cofilin-dependent actin turnover determines platelet forma‐
tion and sizing. Blood 116, 1767 (2010).
[47] M. Bender et al., Microtubule sliding drives proplatelet elongation andis dependent
on cytoplasmic dynein. Blood In Press, (2014).
Production and Destruction of Platelets
http://dx.doi.org/10.5772/60678
21
[48] S. Patel-Hett et al., The spectrin-based membrane skeleton stabilizes mouse megakar‐
yocyte membrane systems and is essential for proplatelet and platelet formation.
Blood 118, 1641 (Aug 11, 2011).
[49] A. Sui et al., Tmod3 participates in platelet formation and sizing in mouse fetal liver
FASEB J 28, 278.9 (2014).
The Non-Thrombotic Role of Platelets in Health and Disease22
